Evidence map›Paper›PMID 39902054›Full record

ArticleFrontiers in immunology2024

Identification of novel clinical subtypes in patients with microscopic polyangiitis using cluster analysis: multicenter REVEAL cohort study.

Ayana Okazaki, Shogo Matsuda, Takuya Kotani, Keisuke Fukui, Takaho Gon, Ryu Watanabe, Atsushi Manabe, Mikihito Shoji, Keiichiro Kadoba, Ryosuke Hiwa and 3 more

Abstract readMulticenter Study
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ayana Okazaki *Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Shogo Matsuda *Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Takuya KotaniDepartment of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Keisuke FukuiFaculty of Societal Safety Sciences, Kansai University, Takatsuki, Japan.
Takaho GonDepartment of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Ryu WatanabeDepartment of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Atsushi ManabeDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Mikihito ShojiDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Keiichiro KadobaDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Ryosuke HiwaDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Wataru YamamotoDepartment of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Japan.
Motomu HashimotoDepartment of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Tohru TakeuchiDepartment of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study aimed to identify new clinical phenotypes of microscopic polyangiitis (MPA) using a principal components analysis (PCA)-based cluster analysis. Methods: A total of 189 patients with MPA between May 2005 and December 2021 were enrolled from a multicenter cohort in Japan (REVEAL cohort). Categorical PCA and cluster analysis were performed based on clinical, laboratory, and radiological findings. Clinical characteristics and outcomes, including all-cause mortality, respiratory-related mortality, end-stage renal disease (ESRD), and relapse were compared between each cluster. Results: Eleven clinical variables were transformed into four components using categorical PCA and synthetic variables were created. Additionally, a cluster analysis was performed using these variables to classify patients with MPA into subgroups. Four distinct clinical subgroups were identified: Cluster 1 included the renal involvements and diffuse alveolar hemorrhage (DAH)-dominant group (N=33). Cluster 2 comprised the elderly onset systemic inflammation group (N=75). Cluster 3 included patients in the younger-onset limited-organ disease group (N=45). Cluster 4 was comprised of an ILD-predominant group without kidney involvement (N=36). 61 patients died during follow-up, with 32 dying of respiratory-related causes. Additionally, 19 patients developed ESRD and 70 relapsed. Cluster 1 showed the worst ESRD-free survival and relapse rates, whereas Cluster 2 showed the worst overall survival and respiratory-related death-free survival rates among the four groups. Conclusions: Our study identified four unique subgroups with different MPA outcomes. Individualized treatments for each subgroup may be required to improve the prognosis of MPA.

Indexed as

Microscopic PolyangiitisAdultAgedAged, 80 and overCluster AnalysisCohort StudiesFemaleHumansJapanKidney Failure, ChronicMaleMiddle AgedPrincipal Component AnalysisPrognosisRecurrencecluster analysisprincipal component analysisprognosisreal world evidencethe running head: clinical subtypes in MPA (microscopic polyangiitis)

Identifiers

PMID39902054
PMCPMC11788177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.